Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to investigate the time course of PF-04764793 concentration in the blood following dosing by oral inhalation from dry powder inhalers.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Treatment A PF-04764793 | Experimental | PF-04764793 using inhaler A |
|
| Treatment B PF-04764793 | Experimental | PF-04764793 using inhaler A |
|
| Treatment C PF-04764793 | Experimental | PF-04764793 using inhaler A |
|
| Treatment D PF-04764793 | Experimental | PF-04764793 using inhaler A |
|
| Treatment E PF-04764793 | Experimental | PF-04764793 using inhaler B |
|
| Treatment F PF-04764793 | Experimental | PF-04764793 using inhaler B |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Treatment A | Drug | PF-04764793 250/50 using inhaler A |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Plasma pharmacokinetic parameter: Area under the curve (AUClast)from the time of dosing to the last data point taken for PF-04764793 | 48 hours | |
| Plasma pharmacokinetic parameter: Maximum concentration (Cmax) for PF-04764793 in plasma. | 48 hours |
| Measure | Description | Time Frame |
|---|---|---|
| Plasma pharmacokinetic parameter: Area under the curve (AUC0-24) from time of dosing to 24 hours post dose for PF-04764793. | 48 hours | |
| Plasma pharmacokinetic parameter: Area under the curve (AUCinf) from the time of dosing extrapolated to infinity for PF-04764793. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer Investigational Site | Singapore | 188770 | Singapore |
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Treatment G PF-04764793 |
| Experimental |
PF-04764793 using inhaler B |
|
| Treatment B |
| Drug |
PF-04764793 250/50 using inhaler A |
|
| Treatment C | Drug | PF-04764793 250/50 using inhaler A |
|
| Treatment D | Drug | PF-04764793 250/50 using inhaler A |
|
| Treatment E | Drug | PF-04764793 250/50 using inhaler B |
|
| Treatment F | Drug | PF-04764793 250/50 using inhaler B |
|
| Treatment G | Drug | PF-04764793 250/50 using inhaler B |
|
| 48 hours |
| Plasma pharmacokinetic parameter: Time of maximum (Tmax) concentration of PF-04764793 in plasma. | 48 hours |
| Plasma pharmacokinetic parameter: Terminal half-life of PF-04764793. | 48 hours |